MARKETWIRE.NET

Decode Your Next Market Move

Global Industry Analysts, Inc. (GIA) launches comprehensive analysis of industry segments, market trends, growth drivers, market share, size and demand forecasts on the global Vascular Closure Devices market. Market segmentation includes Type (Passive Approximators, Active Approximators, and External Hemostatic Devices).

Find Out More About Regions, Brands, Dominant, Active & Niche Companies Covered in the Report

24 November 8:34 a.m., Silicon Valley, California - According to the new market research report, the global market for Vascular Closure Devices is projected to grow at a CAGR of 6.8% reach US$1.2 billion by 2027, driven by increasing number of femoral artery cardiac catheterization, the benefits of reduced hemostasis time, and enhanced patient comfort. Vascular closure devices seal femoral artery punctures in patients who have undergone interventional procedures or diagnostic angiography procedures. In countries across the world, approvals for new vascular closure devices are increasing. This combined with the other factors of rising government support and initiatives and growing demand among patients for more advanced treatment options for cardiovascular diseases is expected to result in steady growth for the market over the long term. Market players aggressively invest in research for new products which is also a major market growth driver. Another important growth driving factor is the higher efficiency rate of the new devices that have entered the market in the recent years.

Prior to vascular closure devices, manual and mechanical compression techniques were used for facilitating access site hemostasis. The techniques however, were ridden with many disadvantages including prolonged hospital stay for patients, increased discomfort, use of more hospital resources and ambulation time delays among others. VCDs, on the other hand, make possible quicker hemostasis leading to more accurate access site closures. Increasing CVDs prevalence leading to rise in cardiovascular procedure numbers, and growing number of new VCD approvals are the major factors supporting growth for the global VCD market since the past few years. CVDs have been one of the major causes behind deaths worldwide for quite some time now. By 2030, the number of deaths due to CVDs is anticipated to reach 24 million, as per the WHO. The significant rise in the number of cardiac interventional procedures therefore is anticipated to create strong demand growth scenario for VCDs over the coming years. Increasing use of imaging technologies for monitoring cardiac functions and radiotherapy has also been creating market growth opportunities as they lead to increase in heart surgeries demand.

Vascular Closure Devices are used for both interventional radiology or vascular surgeries and interventional cardiology with the latter accounting for the larger share in the market attributed to higher prevalence of CVDs and growing percentage of obese people in the world population. Interventional cardiology procedures offer benefits of less pain and reduced scarring because they are minimally invasive. This has been driving increased uptake of VCDs in this application. Interventional cardiologists deploy VCDs for closing arteries following the procedure. The procedures are catheter based treatments targeted at structural heart diseases mainly. They are carried out through blood vessels such as the transradial or transfemoral artery, for stenting and angioplasty.

Research Methodology
This latest edition of the research study is conducted and published by Global Industry Analysts, Inc., in close collaboration with senior executives in the industry driving strategy, business development, marketing, sales, product management, technology and operations. The views, opinions and findings presented are based on validated engagements from a total executive pool size of 10443. Among this pool, 1253 direct interactions with domain experts were carried out via our proprietary market research platform, MarketGlass. Among the 313 unique participations, a total of 141 validated responses were received as part of this report's primary research outreach program. We are unique in the industry to provide our clients with the validated list executive engagements and the complete project data stack.

Key Competitors Covered in the Report -
Abbott Laboratories, Inc.
B. Braun Melsungen AG
Boston Scientific Corporation
Medtronic PLC
Cardinal Health, Inc.
Terumo Corporation
W. L. Gore & Associates, Inc.
Teleflex, Inc.
Cordis, a Cardinal Health company
Merit Medical Systems, Inc.
Endocor GmbH

Segments Covered in the Report -
Type (Passive Approximators, Active Approximators, External Hemostatic Devices)
Procedure (Interventional Cardiology, Interventional Radiology/Vascular Surgery)
Access (Femoral, Radial)

Geographies Analyzed in the Report -
World
USA
Canada
Japan
China
Europe
France
Germany
Italy
UK
Spain
Russia
Rest of Europe
Asia-Pacific
Australia
India
South Korea
Rest of Asia-Pacific
Latin America
Argentina
Brazil
Mexico
Rest of Latin America
Middle East
Iran
Israel
Saudi Arabia
UAE
Rest of Middle East
Africa.

View Executive Engagement Dashboards, COVID Impact Questionnaires & Get Complimentary Access to Methodology & Full-Text Secondary Sources

For enquiries e-mail us at sales@strategyR.com .

For cutting edge analyst reviews on top industries, follow us on Twitter and connect with us on LinkedIn

About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) (www.strategyr.com) is the world`s only influencer driven AI powered market research company. Serving more than 41,000 clients from 36 countries, GIA is recognized for accurate forecasting of markets and industries for 33 years, offering the widest coverage of topics, geographic markets, competitive brands, and companies profiled.

Contact Us:
Zak Ali
Director, Corporate Communications
Global Industry Analysts, Inc.
Phone: 1-408-528-9966
Email: sales@StrategyR.com